PER 3.57% 8.7¢ percheron therapeutics limited

atl1103 successfully progresses towards phase

  1. 10,268 Posts.
    lightbulb Created with Sketch. 697
    ATL1103 Successfully Progresses Towards Phase II Clinical Trial

    ATL1103 Phase I trial successfully meets primary endpoint – safe and well
    tolerated
    ? Preliminary indication of drug activity shown with reduction of serum IGF-I
    and other markers of drug activity
    ? Next step is a Phase II trial in patients with the growth disorder,
    acromegaly
 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
(20min delay)
Last
8.7¢
Change
0.003(3.57%)
Mkt cap ! $78.43M
Open High Low Value Volume
8.4¢ 8.7¢ 8.4¢ $72.99K 855.8K

Buyers (Bids)

No. Vol. Price($)
2 452608 8.4¢
 

Sellers (Offers)

Price($) Vol. No.
8.7¢ 398595 1
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
PER (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.